dimethyl 5,6- dihydro- 7- methoxy- 5,5- dimethyl- 6- (2- (2,5- dioxopyrrolidin- 1- yl)acetyl)- 1H- 1- (4,5- dimethoxycarbonyl- 1,3- dithiolo- 2- spiro)thiopyrano(2,3- c)quinoline- 2,3- dicarboxylate

suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines; structure in first source

Also Known As:

MT477

Networked: 4 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - dimethyl 5,6-dihydro-7-methoxy-5,5-dimethyl-6-(2-(2,5-dioxopyrrolidin-1-yl)acetyl)-1H-1-(4,5-dimethoxycarbonyl-1,3-dithiolo-2-spiro)thiopyrano(2,3-c)quinoline-2,3-dicarboxylate: 4

Experts

1.	Dudek, Arkadiusz Z: 4 articles (04/2011 - 06/2008)
2.	Jasinski, Piotr: 4 articles (04/2011 - 06/2008)
3.	Terai, Kaoru: 4 articles (04/2011 - 06/2008)
4.	Zwolak, Pawel: 4 articles (04/2011 - 06/2008)
5.	Borja-Cacho, Daniel: 2 articles (04/2011 - 02/2011)
6.	Vogel, Rachel Isaksson: 1 article (04/2011)
7.	Galvez, Jorge: 1 article (06/2008)
8.	Ghandi, Lori: 1 article (06/2008)
9.	Land, David: 1 article (06/2008)
10.	Welsh, Brandon: 1 article (06/2008)

Related Diseases

1.	Neoplasms (Cancer) 04/01/2011 - "MiaPaCa-2 tumor xenograft studies showed a 49.5 ±1 4.8% inhibitory effect in mice treated with 100 μg/kg MT477 compared to untreated mice (p=0.0021). " 04/01/2011 - "The present study examined the expression levels of 10,000 genes and how they changed after MT477 treatment in three cancer cell lines: H226, MDA231 and MiaPaCa-2. " 06/01/2008 - "The objective of the present study was to determine the mechanism of action of MT477 and its activity against human cancer cell lines. " 02/01/2011 - "Taken together, these results support the conclusion that MT477 acts as a direct PKC-α inhibitor in non-Ras mutated cancer, with maximum effectiveness when given in a continuous treatment schedule." 02/01/2011 - "H226 tumor size in mice continuously treated with intraperitoneal MT477 (1 mg/kg) was 62.1 ± 15.3% smaller than the average tumor size in control mice. "
2.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/01/2008 - "In this study, MT477 preferentially inhibited the proliferation of K-ras-mutated human pulmonary (A549) and pancreatic (MiaPaCa-2) adenocarcinoma cell lines, compared with a non-Ras-mutated human lung squamous carcinoma cell line (H226) and normal human lung fibroblasts. "
3.	Adenocarcinoma 11/01/2008 - "In this study, MT477 preferentially inhibited the proliferation of K-ras-mutated human pulmonary (A549) and pancreatic (MiaPaCa-2) adenocarcinoma cell lines, compared with a non-Ras-mutated human lung squamous carcinoma cell line (H226) and normal human lung fibroblasts. "
4.	Carcinoma (Carcinomatosis) 06/01/2008 - "MT477 interfered with PKC activity as well as phosphorylation of Ras and ERK1/2 in H226 human lung carcinoma cells. " 06/01/2008 - "Two murine xenograft models of human A431 and H226 lung carcinoma were used to evaluate tumor response to intraperitoneal administration of MT477 (33 microg/kg, 100 microg/kg, and 1 mg/kg). " 06/01/2008 - "A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines."

Related Drugs and Biologics

1.	Protein Isoforms (Isoforms)
2.	quinoline
3.	Aurora Kinase A